-
ESMO BC International Perspective | Professor François Clément Bidard: SERENA-6 Screening Data Highlight the Value of Continuous ESR1 Mutation Monitoring to Precisely Intercept Progression in HR+ Advanced Breast Cancer
ESR1 mutation is a major mechanism of acquired resistance during first-line endocrine therapy for HR+/HER2− advanced breast cancer. At this year’s ESMO Breast Cancer Congress, Professor François Clément Bidard from Institut Curie presented screening-phase data from the SERENA-6 study (Abstract No. 419RO).
-
ESMO BC Global Perspective | Professor Neelima Vidula: Pembrolizumab Plus Carboplatin Did Not Improve Disease Control in Advanced Breast Cancer With Chest Wall Disease, but the Search for Durable Responses Continues
At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Neelima Vidula from Massachusetts General Hospital presented the findings of the randomized phase II ICI-CHEST, TBCRC044 study (Abstract No. 425RO), offering important clinical insights into one of the most challenging settings in advanced breast cancer. The study investigated whether adding the PD-1 inhibitor pembrolizumab to…
-
ESMO BC Global Perspective | Professor Sibylle Loibl: Insights From the INAVO120 Study—The “Counterintuitive” Association Between Hyperglycemia and Improved Outcomes
At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sibylle Loibl from Goethe University Frankfurt presented a post hoc analysis of hyperglycemia in the INAVO120 study. The analysis explored investigator-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and overall survival (OS) according to whether patients experienced hyperglycemia of any grade.
-
ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?
During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor…
-
Oncology Frontier FM · ESMO BC Special | Professor Lajos Pusztai: Neoadjuvant T-DXd-THP Improves Residual Cancer Burden in HER2-Positive Breast Cancer
At the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Lajos Pusztai from Yale University presented an analysis from the neoadjuvant DESTINY-Breast11 (DB-11) study. The results demonstrated that the T-DXd-THP regimen not only increased the pathological complete response (pCR) rate to 67.3%, but also significantly shifted the overall distribution of residual cancer burden (RCB) toward…
-
Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed
Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role…
-
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights
On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis,…
-
Professor Lin Yuehui: Advances and Strategies in Targeted Therapy for Acute Leukemia | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference
To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing…
Connecting Medical Expertise through Media